Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //
Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time

Today's Trading

Day Low 131.34
Day High 133.17
Open:132.75
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
JPMorgan Chase & Co. is a financial services firm. The Company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, asset management and private equity. It offers various investment banking products and services, including advising on corporate strategy and structure, capital-raising in equity and debt markets, risk management, market-making in cash securities and derivative instruments, prime brokerage. It also offers consumer and business, and mortgage banking products and services that include checking and savings accounts, mortgages, home equity and business loans, and investments. JPMorgan Chase & Co. is headquartered in New York.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Latest Press Releases

Marfrig Announces Early Tender Results of: Offer to Purchase for Cash Up to U.S.$1,750,000,000, on a Total Cash Basis, of Outstanding 6.875% Senior Notes due 2025 (CUSIP Nos. 566007 AB6; G5825A AB8 / ISIN Nos. US566007AB67; USG5825AAB82) and 7.000% Senior Notes due 2024 (CUSIP Nos. 566007 AA8; G5825A AA0 / ISIN Nos. US566007AA84; USG5825AAA00) issued, in each case, by MARB BondCo PLC
- PR Newswire - PRF - Tue Jan 26, 4:32PM CST
PR Newswire - PRF - CMTX
Tue Jan 26, 4:32PM CST
S�O PAULO, /PRNewswire/ -- Marfrig Global Foods S.A. (""), MARB BondCo PLC (""), Marfrig Holdings () B.V. (""), Marfrig Overseas Limited (""), HSBC Securities () Inc. (the ""), BNP Paribas Securities Corp., Banco Bradesco BBI S.A., HSBC Securities () Inc., Jefferies LLC, J.P. Morgan Securities LLC, Santander Investment Securities Inc., Banco BTG Pactual S.A. – Cayman Branch, Banco Safra S.A., acting through its Branch, Itau BBA Securities, Inc., Rabo Securities , Inc. and UBS Securities LLC (the "") today announced the early tender results of the Purchaser's previously announced offers to purchase for cash from each registered holder (each, a "" and, collectively, the "") up to U.S., on a total cash basis, that Purchaser will accept for purchase (the "") of the (i) outstanding 6.875% Senior Notes due 2025 (the "") issued on by MARB (the "") and (ii) outstanding 7.000% Senior Notes due 2024 (the "" and, together with the 2025 Notes, the "") issued on by MARB (the "" and, together with the 2025 Offer, the ""). As previously announced, the early tender deadline for the Offer was time, on (such date and time, the "Early Tender Time" and "").
JPMorgan Chase to Present at the Credit Suisse Financial Services Forum
- BusinessWire - Tue Jan 26, 9:09AM CST
BusinessWire - CMTX
Tue Jan 26, 9:09AM CST
Jennifer Piepszak, Chief Financial Officer of JPMorgan Chase & Co., will present at the Credit Suisse Financial Services Forum on Thursday, February 25, 2021 at 9:40 a.m. (Eastern). The conference will be held virtually.
CytomX Therapeutics Announces Closing of Public Offering of Common Stock
- GlobeNewswire - Tue Jan 26, 7:00AM CST
GlobeNewswire - CMTX
Tue Jan 26, 7:00AM CST
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies, today announced the completion of its previously announced underwritten public offering of 14,285,714 shares of its common stock at a price to the public of $7.00 per share, with net proceeds to CytomX of approximately $93.6 million, after deducting underwriting discounts and commissions and estimated offering expenses. All shares in the offering were sold by CytomX. In addition, CytomX has granted the underwriters of the offering a 30-day option to purchase up to an additional 2,142,857 shares of its common stock at the public offering price, on the same terms and conditions.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 123.77 +6.31% increase
on 01/05/21
Period Open:124.52
Price movement based on the high, low and last over the given period.
142.75 -7.82% decrease
on 01/14/21
+7.06 (+5.67%) increase
since 12/24/20
3-Month 95.24 +38.16% increase
on 10/29/20
Period Open:101.24
Price movement based on the high, low and last over the given period.
142.75 -7.82% decrease
on 01/14/21
+30.34 (+29.97%) increase
since 10/26/20
52-Week 76.91 +71.08% increase
on 03/19/20
Period Open:133.15
Price movement based on the high, low and last over the given period.
142.75 -7.82% decrease
on 01/14/21
-1.57 (-1.18%) decrease
since 01/24/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies